Fortrea Beats Revenue Estimates, Misses Earnings
Update: 2025-11-12
Description
Fortreas Q3 earnings show robust revenue growth, surpassing analyst estimates by nearly 10%, driven by clinical pharmacology and development businesses. The company attributes this success to operational improvements and new technology, doubling win rates with biotech clients and securing high volumes of new business. However, adjusted earnings per share missed expectations due to higher pass-through costs. Fortrea raised its full-year revenue and EBITDA guidance, with investors reacting positively to the companys focus on operations and technology.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
